A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...
Hosted on MSN6mon
Roche’s BTK inhibitor shines in multiple sclerosis trialThe OLE followed a 12-week, double-blind Phase II trial. This update comes just days after Sanofi shared mixed results from its BTK inhibitor, tolebrutinib, with the HERCULES trial meeting its ...
Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who ...
Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...
The pause affects the HERCULES trial in non-relapsing secondary progressive MS, the PERSEUS study in primary progressive MS, and URSA in myasthenia gravis "Patient safety remains our top priority ...
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was able to delay the time to six-month disability progression by 31% ...
A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results